Exosomes
Exosomes and small extracellular vesicles
Written by Aaron CuhaReviewed Sep 2026
Also known as: Extracellular vesicles, EVs, MSC-exosomes, Small EVs, Exosome therapy
A randomised trial in 110 people with diabetic foot ulcers found faster healing. Almost nothing sold in a clinic resembles that preparation, and the field published a standards document because it could not consistently describe what it was studying.
Overview
Exosomes are the most interesting thing on this site that cannot be evaluated as a single product, and understanding why is more useful than any individual result.
They are small vesicles that cells release to carry proteins, lipids and nucleic acids to other cells. That is real biology and it is not in dispute. The therapeutic idea follows naturally: harvest the vesicles that stem cells release, give those instead of the cells, and get the signalling without transplanting living tissue.
There is genuine human evidence. A randomised trial in 110 people with chronic diabetic foot ulcers compared topical Wharton's jelly mesenchymal stem cell exosomes plus standard care against standard care alone and against the vehicle. The treated group healed in a mean of 6 weeks against 20 weeks in controls.
The problem is everything else. An exosome preparation is a population, not a compound. Cargo, purity, dose and potency vary with the source cell, the culture conditions and the isolation method, and the field's own standards document exists precisely because researchers could not consistently characterise what they were studying. So a positive trial of one preparation in one indication says very little about a vial in a clinic.
Mechanism of action
Small extracellular vesicles, generally 30 to 150 nanometres, formed inside multivesicular bodies and released when those fuse with the cell membrane. They carry proteins, lipids, messenger RNA and microRNA, and they transfer that cargo to recipient cells, altering gene expression and behaviour. In the therapeutic context the cargo is the drug rather than the vesicle: the proposed effects on wound healing, inflammation and tissue repair come from what the vesicle is carrying, which depends on the source cell and how it was cultured. That is the crux of the characterisation problem. Two preparations of identical size and count can carry entirely different cargo, and nothing about the label tells you which you have.
Human evidence
One well-designed randomised trial with a strong result in a specific indication with a specific preparation, a thin cosmetic literature, and a large commercial market running far ahead of both.
- 110 patients with chronic diabetic foot ulcers: mean time to full recovery 6 weeks on topical exosomes plus standard care against 20 weeks on controls, with significantly more patients fully recovered.
- That trial included a vehicle arm, which matters because the carrier alone can affect a wound and most studies in this field omit it.
- The hair loss literature, which is where most consumers meet these products, is reviewed rather than settled and is much thinner than the marketing suggests.
- No exosome product is approved anywhere for any indication.
- The field published a consensus standards document because vesicle preparations could not be consistently characterised or compared between laboratories.
- Analysis of direct-to-consumer marketing found businesses making claims about regulatory status that need checking against the fact that nothing is approved.
What this does not tell you: The strong result is one trial, four weeks of treatment, in one indication, using one preparation from one source tissue applied topically to a wound. None of that transfers to an intravenous infusion, a facial, a joint injection or a scalp treatment, and none of it transfers to a different preparation. Because there is no approved product and no standardised characterisation, a clinic cannot tell you the dose, the potency or the cargo of what it is selling, and in most cases nobody has measured them. Absence of a trial here is also absence of safety data: sterility is a real concern for a biological product prepared outside an approved manufacturing process.
Reading the research record
This page is deliberately harder on the category than on the trial, and the reason is worth stating.
The diabetic foot ulcer result is good work. Randomised, three arms including a vehicle control, a clinically meaningful endpoint, and a large effect. If exosome therapy becomes real medicine, trials like that are how it happens, and the biology underneath is sound.
But the gap between that trial and the market is the widest on this site. Everywhere else, the usual gap is between a promising mechanism and a missing trial. Here there is a trial, and the problem is that the thing tested cannot be identified with the thing sold. An exosome preparation is defined by its cargo, its cargo depends on the source cell and the culture conditions, and the field needed a consensus document to agree on how to describe any of it. So when a clinic offers exosomes, the word names a category of particle, not a product with known contents.
The practical consequence is that the ordinary question, does this work, has no answer at the category level. It has an answer for one preparation applied topically to diabetic ulcers, and no answer at all for the infusion or facial being sold, including on safety, since a biological product made outside an approved manufacturing process carries sterility risk that no amount of mechanism reassures you about.
The evidence, charted
Fig. 1 · evidence composition
1of 4 citations (25%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2023 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2025
The transforming role of Wharton's jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial
110 patients with chronic diabetic foot ulcers randomised to three arms: weekly topical Wharton's jelly mesenchymal stem cell exosomes plus standard of care, standard of care alone, or standard of care plus the exosome vehicle, over four weeks. 53 patients (62%) fully recovered by the end of the study, significantly more in the treated group than in controls. Mean time to full recovery was 6 weeks in the treated group (range 4 to 8) against 20 weeks in controls (range 12 to 28). Including a vehicle arm is the right design and is unusual in this field.
Stem Cell Research and Therapy - Review2024
Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches
The field's own standards document, and the single most important citation on this page. It exists because researchers could not consistently describe, characterise or compare the vesicle preparations they were studying. A discipline that needs a consensus document defining what counts as its object of study is not a discipline where a clinic can credibly tell you what is in a vial.
Journal of Extracellular Vesicles - Review2025
Exosomes for treating hair loss: a review of clinical studies
A review of the clinical studies behind one of the most heavily marketed cosmetic uses. Relevant because hair loss is where most consumers first encounter an exosome product, and the clinical literature behind it is much thinner than the marketing.
Dermatologic Surgery - Review2023
Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies
An analysis of what businesses selling these therapies directly to consumers actually claim about their regulatory status. The commercial reality check for anyone who has been told in a clinic that a product is approved, registered or FDA-compliant.
Regenerative Medicine
Frequently asked questions
Do exosomes work?
For one preparation, applied topically, in chronic diabetic foot ulcers, a randomised trial in 110 people found healing in a mean of 6 weeks against 20 in controls. For anything else being sold, the honest answer is that nobody knows, because an exosome preparation is defined by its cargo and no two products are the same thing.
Why can you not just say whether the category works?
Because it is not a compound. It is a population of vesicles whose contents depend on which cells made them and how those cells were grown. The field published a consensus standards document precisely because researchers could not consistently characterise or compare preparations. A positive result for one tells you very little about another.
Is the exosome treatment my clinic offers approved?
No. No exosome product is approved for any indication in the United States, the United Kingdom, Australia or Canada. If a clinic has told you otherwise, that specific claim has been studied: an analysis of direct-to-consumer marketing in this sector examined the regulatory claims these businesses make.
Are they safe?
Unestablished, and the risk is not hypothetical in the way it is for most things here. This is a biological product, so a preparation made outside an approved manufacturing process carries contamination and sterility risk on top of the unknown effects of unknown cargo. Absence of trials is absence of safety data, not evidence of safety.
What about exosomes for hair loss?
That is where most people first encounter them and the clinical literature is much thinner than the marketing. A 2025 review surveyed the clinical studies that exist; it is a review of an emerging area rather than a settled answer, and the same identification problem applies: the product in the clinic is not the preparation in the study.